Affiris raises €10m from MIG et al.

Affiris stated it has attracted €130m of funding to date, of which half comes from licence income and government grants.

An adapted management structure and the fresh capital are supposed to support the development of its vaccines, both pre-clinical and clinical.

The company's supervisory board appointed Günther Staffler as chief technology officer. Staffler was previously Affiris's head of immunology. Noel Barrett has joined the supervisory board this month.

MIG is currently investing from its 15th fund, which is still fundraising with a target of €70m and a hard-cap of €100m. Affiris is the vehicle's seventh portfolio company.

Previous funding
In November 2011, MIG and Santo VC invested €25m in Affiris. Santo VC invested €20m and MIG invested €5m in the transaction.

In November 2008, MIG invested €3m in Affiris via its MIG 5 and MIG 7 vehicles. In April 2006, MIG invested €8.5m in the company.

Company
Founded in 2003 and based in Vienna, Affiris develops therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of three drug candidates against Parkinson's, MSA and hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma and Huntington's disease are in pre-clinical development. Affiris employs 60 staff.

People
MIG – Michael Motschmann (chairman supervisory board).
Affiris – Oliver Siegel (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Austria